AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ocular Therapeutix Sets 2025 as Transformative Year with Advancements in Wet AMD Trials and Extended Cash Runway into 2028.
ByAinvest
Tuesday, Nov 4, 2025 3:19 pm ET1min read
Ocular Therapeutix has outlined milestones for its superiority trial and a broad diabetic label strategy, extending its cash runway into 2028. CEO Pravin Dugel described 2025 as a transformative year for the company, highlighting the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. SOL-R has reached its target randomization of 180 patients.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet